FindTrial
Sign In

Markers for predicting response to compound Qinghuang Powder (QHP) based on the gene sequencing and the combination of disease and syndrome in patients with myelodysplastic syndromes

Markers for predicting response to compound Qinghuang Powder (QHP) based on the gene sequencing and the combination of disease and syndrome in patients with myelodysplastic syndromes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RNC-17014235
Enrollment
Unknown
Registered
2017-12-30
Start date
2017-01-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndrome

Interventions

Case series:compound Qinghuang Powder (QHP)

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria for Western medicine MDS and voluntary treatment of traditional Chinese medicine Qinghuang powder treatment; 2. voluntarily tested and signed informed consent; 3. did not participate in other clinical researchers

Exclusion criteria

Exclusion criteria: 1. combined with serious intentions, liver, kidney and peripheral neurological disease; 2. mental illness can not cooperate with the treatment of patients; 3. pregnancy, lactating women; 4. less than 18 years of age, more than 75 years of age; 5. participate in other clinical researchers; 6. patients can not cooperate or do not sign informed consent.

Design outcomes

Primary

MeasureTime frame
gene sequencing;Effect;—

Contacts

Public ContactHu Xiaomei

Xiyuan Hospital, China Academy of Chinese Medical Sciences

huxiaomei_2@163.com+86 18610350593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026